Ignite Creation Date:
2025-12-25 @ 2:24 AM
Ignite Modification Date:
2025-12-27 @ 4:05 AM
Study NCT ID:
NCT06125834
Status:
RECRUITING
Last Update Posted:
2024-04-16
First Post:
2023-10-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Progressive Disease After TKIs or HP Therapy
Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-06-01
Start Date Type:
ACTUAL
Primary Completion Date:
2025-04-30
Primary Completion Date Type:
ESTIMATED
Completion Date:
2026-05-31
Completion Date Type:
ESTIMATED
First Submit Date:
2023-10-29
First Submit QC Date:
None
Study First Post Date:
2023-11-09
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-15
Last Update Post Date:
2024-04-16
Last Update Post Date Type:
ACTUAL